title: [S-1 plus Cisplatin Combination Therapy for Gastric Cancer with Peritoneal Dissemination].
abstract: Peritoneal dissemination (PD) is the most common type of metastasis in advanced gastric cancer. The standard treatment of gastric cancer patients with PD is combination therapy with S-1 and cisplatin (SP therapy). Here, we describe the results of SP therapy for gastric cancer with PD. Sixteen gastric cancer patients with PD were treated with SP therapy as first-line chemotherapy. Second-look staging laparoscopy was performed for 10 patients who showed a good response to SP therapy. Gastrectomy was performed for 5 patients with P0CY0 and 1 case with P0CY1. The median survival time of all 16 patients was 571 days (19 months). The patients, who had surgery, had a significantly better survival time than the others (25 months vs 12.7 months). In conclusion, SP therapy is effective for gastric cancer with PD, and surgery for cases showing a good response to chemotherapy might improve the prognosis of patients with PD.
authors.affiliation: Dept. of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: Takeo
authors.initials: T
authors.lastname: Hara
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Keijiro
authors.initials: K
authors.lastname: Sugimura
authors.forename: Takeshi
authors.initials: T
authors.lastname: Omori
authors.forename: Masaaki
authors.initials: M
authors.lastname: Motoori
authors.forename: Norikatsu
authors.initials: N
authors.lastname: Miyoshi
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Akita
authors.forename: Kunihito
authors.initials: K
authors.lastname: Gotoh
authors.forename: Hidenori
authors.initials: H
authors.lastname: Takahashi
authors.forename: Shogo
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Shingo
authors.initials: S
authors.lastname: Noura
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ohue
authors.forename: Masato
authors.initials: M
authors.lastname: Sakon
authors.forename: Masahiko
authors.initials: M
authors.lastname: Yano
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin